Last reviewed · How we verify
NCT06700590: FLIP-IT
First-Line Intervention for PTSD - Intensive Treatment
NA trial testing Intensive Treatment in PTSD - Post Traumatic Stress Disorder in 186 participants. Currently enrolling.
1 April 2028
Quick facts
| Lead sponsor | ARQ National Psychotrauma Centre |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 186 |
| Start date | 21 November 2024 |
| Primary completion | 1 April 2028 |
| Estimated completion | 1 July 2028 |
| Sites | 4 locations across Netherlands |
Drugs / interventions tested
- Intensive Treatment — full drug profile →
- Treatment as usual
Conditions studied
- PTSD - Post Traumatic Stress Disorder — all drugs for PTSD - Post Traumatic Stress Disorder →
Sponsor
ARQ National Psychotrauma Centre — full company profile →
Who can join
18 and older, any sex, with PTSD - Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if an intensive program can treat post-traumatic stress disorder (PTSD) in adults getting treatment for the first time, and whether it has lower societal costs. The main questions it aims to answer are: * Does an intensive program reduce PTSD symptoms? * How expensive is it on a societal level? Researchers will compare the intensive program to the standard weekly treatment to see if the intensive program works to treat PTSD. Participants will: * Get 5 days of intensive treatment in two weeks (with two preparatory and closing sessions), or weekly sessions * Get questionnaires and interviews 5 times in 9 months
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cost-effectiveness of massed versus spaced trauma-focused treatment as first-line treatment for post-traumatic stress disorder in adults with multiple trauma exposure: protocol for a single-blind non-inferiority randomised controlled trial.
Kemmere B, van Pelt YT, Lommen MJJ, Huntjens RJC, et al · · 2025 · PMID 40409963 · DOI 10.1136/bmjopen-2025-102530
Verify or expand the search:
- PubMed search for NCT06700590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intensive Treatment
Trials testing the same drug.
- NCT03755362 — Dental Carotid Cognitive Study · NA · terminated
- NCT03354143 — Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) · Phase 2 · completed
- NCT01120067 — Intensive Treatment for Chronic Pain and Posttraumatic Stress Disorder (PTSD) · NA · completed
Other recruiting trials for PTSD - Post Traumatic Stress Disorder
Currently open trials in the same condition.
- NCT07410481 — Trial of Acceptance and Mindfulness-based Exposure Therapy (AMBET) and Present Centered Therapy (PCT) · NA · recruiting
- NCT07473362 — Hyperbaric Oxygen Therapy for Post Traumatic Stress Disorder - a Pragmatic, Double Blinded Randomized Trial · NA · recruiting
- NCT07525284 — Reported Experience Measurement on Reducing Patient Discomfort in Intensive Care · NA · recruiting
- NCT07368166 — Development of the PTSD-iMPACT to Measure PTSD-Related Functional Impairment in Children and Adolescents - A Validation · recruiting
- NCT07069517 — Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06700590 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ARQ National Psychotrauma Centre
- Last refreshed: 3 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06700590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing